Bank of New York Mellon Corp cut its position in Xencor Inc (NASDAQ:XNCR) by 2.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 196,332 shares of the biopharmaceutical company’s stock after selling 4,743 shares during the quarter. Bank of New York Mellon Corp owned about 0.42% of Xencor worth $4,500,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Emory University acquired a new position in Xencor in the 2nd quarter valued at $1,491,000. State Street Corp raised its holdings in Xencor by 11.1% in the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after acquiring an additional 110,474 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Xencor in the 2nd quarter valued at $612,000. Vanguard Group Inc. raised its holdings in Xencor by 5.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after acquiring an additional 90,094 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Xencor by 6.6% in the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock valued at $10,527,000 after acquiring an additional 30,715 shares in the last quarter. Institutional investors and hedge funds own 77.50% of the company’s stock.
In other news, major shareholder John S. Stafford III bought 6,215 shares of the stock in a transaction on Tuesday, December 12th. The stock was acquired at an average price of $20.72 per share, with a total value of $128,774.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder John S. Stafford III bought 9,215 shares of the stock in a transaction on Thursday, December 14th. The stock was purchased at an average cost of $20.76 per share, with a total value of $191,303.40. The disclosure for this purchase can be found here. Insiders have bought a total of 278,535 shares of company stock valued at $5,526,936 in the last three months. 4.14% of the stock is owned by insiders.
Xencor Inc (XNCR) opened at $22.80 on Wednesday. Xencor Inc has a fifty-two week low of $18.55 and a fifty-two week high of $28.64. The company has a market capitalization of $1,070.00, a price-to-earnings ratio of -22.57 and a beta of 2.09.
Several equities analysts have weighed in on XNCR shares. Canaccord Genuity set a $36.00 price objective on Xencor and gave the company a “buy” rating in a report on Monday, October 23rd. Cantor Fitzgerald started coverage on Xencor in a report on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 price objective for the company. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a report on Wednesday, November 22nd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. Finally, BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a report on Thursday, December 7th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $30.80.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/01/03/xencor-inc-xncr-shares-sold-by-bank-of-new-york-mellon-corp.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.